Dyne Therapeutics, Inc. (DYN)
16.59
-0.57
(-3.32%)
USD |
NASDAQ |
Nov 16, 14:12
Dyne Therapeutics Total Liabilities (Quarterly) : 303.87M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 303.87M |
| June 30, 2026 | 291.86M |
| March 31, 2026 | 214.90M |
| December 31, 2025 | 214.83M |
| September 30, 2025 | 175.28M |
| June 30, 2025 | 157.55M |
| March 31, 2025 | 52.10M |
| December 31, 2024 | 61.40M |
| September 30, 2024 | 63.30M |
| June 30, 2024 | 50.69M |
| March 31, 2024 | 44.22M |
| December 31, 2023 | 73.79M |
| September 30, 2023 | 53.21M |
| June 30, 2023 | 44.54M |
| Date | Value |
|---|---|
| March 31, 2023 | 46.71M |
| December 31, 2022 | 53.96M |
| September 30, 2022 | 49.94M |
| June 30, 2022 | 52.97M |
| March 31, 2022 | 51.30M |
| December 31, 2021 | 57.47M |
| September 30, 2021 | 52.76M |
| June 30, 2021 | 14.55M |
| March 31, 2021 | 13.45M |
| December 31, 2020 | 10.97M |
| September 30, 2020 | 14.63M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 2.40M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 357.70M |
| Amgen, Inc. | 81.70B |
| Anika Therapeutics, Inc. | 52.02M |
| BioCryst Pharmaceuticals, Inc. | 988.45M |
| Imunon, Inc. | 9.386M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.235B |
| Shareholders Equity (Quarterly) | 930.93M |
| Debt to Equity Ratio | 0.2624 |
| Current Ratio | 12.99 |
| Net Debt Paydown Yield | -0.82% |